Wednesday, September 10, 2014 6:22:53 PM
>>Price gouging is rampant from rare disease companies. The model needs to change.
Right.
They should not be able to charge more for a drug that only has 2,000 potential patients than one that has 2,000,000.
Of course, then the 2,000 would not get treatments. There is no free lunch and when government makes approvals cost hundreds of millions, those costs will get paid or the work will not be done.
Right.
They should not be able to charge more for a drug that only has 2,000 potential patients than one that has 2,000,000.
Of course, then the 2,000 would not get treatments. There is no free lunch and when government makes approvals cost hundreds of millions, those costs will get paid or the work will not be done.
It is astonishing what foolish things one can temporarily believe if one thinks too long alone ... where it is often impossible to bring one's ideas to a conclusive test either formal or experimental. J.M. Keynes
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
